Theranostics Market - Size, Outlook, and
Opportunity Analysis, 2018 – 2026
Theranostics involves combination of targeted diagnostic tests with targeted therapy. It is also
known
as
companion
diagnostics,
integrated
medicine,
Dx/Rx
partnering,
and
pharmacodiagnostics. Implementation of theranostics into the patient care plan (in case of
selected diseases for which diagnostic tests are available along with respective therapy) may
turn into personalized therapy, which could further improve medical outcomes.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/2043
Theranostics include use of specific diagnostic test, which shows a particular molecular target
on a tumor or any other disease causing agent. Any disease pathophysiology involves specific
biological pathways, which are targeted with the help of diagnostic tests. Diagnostic images of
the particular molecule then identifies presence of the specific mutation or receptors (in case of
cancer), which can be targeted with the help of therapeutic agents. This approach avoids trial
and error treatment and could be used to offer patient specific treatment at the right time.
Accurate dose calibration and precisely targeted approach could highly be useful in management
of chronic diseases such as cancer.
For instance, neuro endocrine tumors can be diagnosed to assess extent of disease via PET-CT
(Positron Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive
positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor cell membrane, and
is injected through vein, which travels and binds to the SSTR2 indication the presence of tumor
on PET scan. Furthermore, Ga-68 can be replaced by a therapeutic agent to target the tumor.
Global Theranostics Market Drivers:-
Development of novel companion diagnostic tests to be used with available treatment options is
expected to boost the global theranostics market growth over the forecast period. Leading
manufacturers are engaged in introduction of novel companion diagnostic tests in market. For
instance, Illumina, Inc. announced launch of the U.S. Food & Drug Administration (FDA)
approved extended RAS panel for identification of patients eligible for treatment of metastatic
colorectal cancer with Vectibix (panitumumab) in 2017.